Evaluation of the Efficacy of the Addition of Magnesium Sulfate to Morphine on the Occurrence of Acute Urinary Retention Following Epidural Anesthesia for Cesarean Section.
NCT ID: NCT06442995
Last Updated: 2025-12-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
290 participants
INTERVENTIONAL
2025-01-16
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a particularly debilitating event for parturients, exposing them to the risk of further urinary catheterization, increased theoretical risk of urinary tract infection, traumatic urethral injury, hindered accelerated rehabilitation and altered maternal satisfaction.
Several studies have demonstrated the benefits of adding magnesium sulfate to epidural anesthesia for Caesarean sections, notably by reducing postoperative pain.
Magnesium sulfate may also have a facilitating effect on postoperative micturition, thanks to its sympathicolytic effect.
This hypothesis is supported by a retrospective study carried out in our maternity hospital, which showed a 15% reduction in post-Caesarean urinary retention when women were given magnesium sulfate in addition to the drugs traditionally used for epidurals.
This little-known property needs to be clarified
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In fact, the incidence of acute urine retention after epidural anaesthesia for Caesarean section is around 33%. Two encouraging studies suggest that adding magnesium sulfate to epidurals could reduce the incidence of acute urine retention by 15%.
This study will be carried out on the obstetric population of the REIMS maternity hospital, starting in summer 2024. It is a randomized, double-blind, placebo-controlled clinical trial. The number of subjects required is calculated at 290 patients, with a power of 80% and an alpha risk of 5%. The statistical hypothesis is that magnesium sulfate reduces the incidence of acute urine retention by 15% compared with placebo (isotonic saline).
Parturients will be informed of the study during a pre-anaesthetic consultation in the 6th month of pregnancy.
Some of these patients will be scheduled for delivery by caesarean section. The remaining patients will be scheduled for a vaginal delivery, which may end up being an emergency caesarean section (10-15% of patients).
After the Caesarean section, patients are taken to the post-procedure monitoring room, where they are monitored for 2 hours.
It is at this point that patients are examined to verify the inclusion and non-inclusion criteria of the protocol. If the inclusion and non-inclusion criteria are met, our teams will provide patients with explanatory documents on our protocol, as well as a consent form for their signature.
When the patient agrees to enter the protocol, the investigators randomize her to one of the following groups:
* Group A: injection of morphine 2 mg into the epidural catheter + magnesium sulfate 500 mg
* Group B: injection of morphine 2 mg into the epidural catheter + isotonic saline.
Group B is the control group. This is the protocol we use in daily practice for parturients who have undergone Caesarean section, in line with the French recommendations of anesthesia societies.
This reduces the parturient's postoperative pain for 20-24 hours. Group A will be the experimental group. Patients will be monitored in the post-natal care unit for 72 hours. The investigators will carry out the same monitoring and care as a parturient outside the protocol. Various data on diuresis, the quantity of urine in the bladder visualized by ultrasound, and the need for urinary catheterization will be recorded.
Statistical analyses will determine whether the incidence of acute urine retention differs between each group.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Magnesium Sulfate
Injection of 500 mg magnesium sulfate + 2 mg morphine into the epidural space
Injection of 500 mg magnesium sulfate + 2 mg morphine into the epidural space
When the patient agrees to enter the protocol, the investigators randomize the patient and proceed to the injection of morphine 2 mg into the epidural catheter + magnesium sulfate 500 mg
Isotonic saline
Injection of Isotonic saline + 2 mg morphine into the epidural space
Injection of Isotonic saline + 2 mg morphine into the epidural space
When the patient agrees to enter the protocol, the investigators randomize the patient and proceed to Injection of morphine 2 mg into the epidural catheter + isotonic saline. This is the protocol the investigators use in daily practice for parturients who have undergone Caesarean section, in line with the French recommendations of anesthesia societies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Injection of 500 mg magnesium sulfate + 2 mg morphine into the epidural space
When the patient agrees to enter the protocol, the investigators randomize the patient and proceed to the injection of morphine 2 mg into the epidural catheter + magnesium sulfate 500 mg
Injection of Isotonic saline + 2 mg morphine into the epidural space
When the patient agrees to enter the protocol, the investigators randomize the patient and proceed to Injection of morphine 2 mg into the epidural catheter + isotonic saline. This is the protocol the investigators use in daily practice for parturients who have undergone Caesarean section, in line with the French recommendations of anesthesia societies
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who have just undergone caesarean section and have the epidural catheter in place in the post-interventional monitoring room (SSPI).
* Patients who agree to take part in the research and have signed the informed consent form
* Patients of legal age
* Patients affiliated to a social security scheme
Exclusion Criteria
* Patients protected by law
* Patients allergic to local anesthetics, morphine or magnesium sulfate
* Patients with severe renal insufficiency (GFR \< 30 ml/min)
* Patients with pre-pregnancy mictional disorders
* Patients with an American Society of Anesthesiologists (ASA) score of 4
* Patients undergoing caesarean section under general anaesthesia, after failure of perimedullary anaesthesia
* Patients with accidental intraoperative injury to the urinary tract
* Patients who have received intravenous magnesium sulfate in the 24 hours preceding cesarean section
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CHU de Reims
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Reims
Reims, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Damien JOLLY
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PO24038*
Identifier Type: -
Identifier Source: org_study_id